A RISK-BENEFIT ASSESSMENT OF DRUGS USED IN THE MANAGEMENT OF PARKINSONS-DISEASE

被引：10

作者：

BODAGH, IYO ^{[1
]}

ROBERTSON, DRC ^{[1
]}

机构：

[1] ST MARTINS HOSP,BATH & W COMMUNITY NHS TRUST,MIDFORD RD,BATH BA2 5RP,AVON,ENGLAND

来源：

DRUG SAFETY | 1994年 / 11卷 / 02期

关键词：

D O I：

10.2165/00002018-199411020-00004

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

The introduction of levodopa therapy in the 1960s and subsequent advances in neuropharmacology have revolutionised the management of Parkinson's disease - but at a cost. Adverse effects are common, and an erratic pattern of response may develop with long term therapy due to a poorly understood interaction between drug treatment and disease progression. Not all features of the disease respond to drugs, and certain aspects such as psychiatric symptoms and postural imbalance may indeed be exacerbated. Patients vary considerably in their tolerance of anti-Parkinsonian drugs. Individual assessment of each patient's medical, psychiatric and functional problems is required, with ongoing review and dose titration as the disease progresses. In recent years there has been increasing interest in whether it is possible to influence the progression of Parkinson's disease. As a result, more complicated drug regimens are being advocated for use in newly diagnosed patients. Arguments for and against this approach, as opposed to traditional symptomatic treatment, are presented.

引用

页码：94 / 103

页数：10

共 65 条

[1] Quinn N.P., Antiparkinsonian drugs today, Drugs, 28, (1984)
[2] Molloy D.W., Brooymans M., Anticholinergic medication and cognitive function in the elderly, J Clin Exp Gerontol, 10, pp. 89-98, (1989)
[3] Gribbin B., Pickering T.G., Sleight P., Et al., Effect of age and high blood pressure on baroreflex sensitivity in man, Circ Res, 29, (1971)
[4] Ruberg M., Ploska A., Javoy-Agid F., Et al., Muscarinic binding and choline transferase activity in parkinsonian subjects with reference to dementia, Brain Res, 232, (1982)
[5] Perry R.H., Tomlinson B.E., Candy J.M., Et al., Cortical cholinergic deficit in mentally impaired parkinsonian patients, Lancet, 2, (1983)
[6] Horrocks P.M., Vicary D.K., Rees J.E., Et al., Anticholinergic withdrawal and benzhexol treatment of Parkinson’s disease, J Neurol Neurosurg Psychiatry, 36, (1973)
[7] Schwab R.S., England A.C., Poskanzer D.C., Et al., Amantadine in the treatment of Parkinson’s disease, JAMA, 208, (1969)
[8] Nastuk W.L., Su P., Doubilet P., Anticholinergic and membrane activities of amantadine in neuromuscular transmission, Nature, 264, (1976)
[9] Gianutsos G., Chute S., Dunn J.P., Pharmacological changes in dompaminergic systems induced by long-term administration of amantadine, Eur J Pharmacol, 110, (1985)
[10] Kornhuber J., Bormann J., Retz W., Et al., Memantine displaces [3H] MK-801 at therapeutic concentrations in post mortem frontal cortex, Eur J Pharmacol, 166, (1989)

← 1 2 3 4 5 6 7 →